Associate Professor Tahsin Ozatli
5
reviews
Tahsin Ozatli is a medical oncologist with more than 20 years of experience. He sees adults with a confirmed or suspected cancer diagnosis, reviews examination results, and develops a personalized systemic treatment plan based on the tumor type, disease stage, molecular features, and the patient’s overall condition.
Conditions treated by Dr Ozatli include:
- lung cancer;
- breast cancer;
- stomach and esophageal cancer;
- colorectal cancer and other gastrointestinal tumors;
- gastrointestinal stromal tumors (GIST);
- advanced and metastatic solid tumors requiring a second opinion or treatment-plan review.
Alongside his clinical practice, Tahsin Ozatli is involved in academic work at Istinye University in medical oncology and internal medicine. His research addresses issues that directly influence treatment choices, including EGFR mutation analysis in non-small cell lung cancer, multimodal treatment of complex lung tumors, and combined treatment for operable gastric cancer.
This academic focus matters to patients because the doctor evaluates not only the tumor site and stage, but also its biological features, treatment tolerability, and outcomes associated with different approaches. His professional portfolio also includes publications on denosumab for metastatic giant cell tumor of bone and the clinical features of rare cancer cases.
Why patients choose Dr Ozatli:
- more than 20 years of clinical practice in medical oncology;
- experience with chemotherapy, immunotherapy, targeted therapy, and hormone therapy;
- individual treatment selection based on histology, molecular testing, and imaging;
- multidisciplinary cooperation with surgeons, radiologists, and radiation oncologists;
- clear discussion of treatment goals, expected outcomes, and possible side effects.
To travel for treatment with Tahsin Ozatli, prepare your medical reports, laboratory results, CT, MRI or PET-CT images, and the biopsy report. The Experts Medical team will help send the documents to the doctor, obtain a preliminary opinion, and organize your visit to the clinic.
Achievements and awards
About doctor Tahsin Ozatli
Tahsin Ozatli is a medical oncologist. He diagnoses and provides systemic treatment for malignant tumors, including the selection of chemotherapy, targeted therapy, and immunotherapy according to the diagnosis and stage of the disease.
Main areas of treatment:
- lung cancer;
- breast cancer;
- digestive system tumors: cancers of the esophagus, stomach, and intestines;
- gynecological tumors: ovarian, uterine, and primary peritoneal cancer;
- kidney cancer;
- sarcomas, neuroendocrine tumors, and other rare tumors;
- modern chemotherapy, targeted therapy, immunotherapy, and hormone therapy regimens;
- molecular genetic tumor profiling and individualized treatment selection in accordance with international clinical guidelines.
- 2002: graduated from Meram Faculty of Medicine, Selcuk University.
- 2009: completed internal medicine specialization at Izmir Ataturk Training and Research Hospital and qualified as an internal medicine specialist.
- 2011–2015: completed subspecialty training in medical oncology at Ankara Oncology Training and Research Hospital.
- 2002–2003: general practitioner at Kirikkale Irmak Primary Health Care Center; completed compulsory public service.
- March 2009 — March 2010: completed military service at Balikesir Non-Commissioned Officer Vocational School.
- March 2010 — July 2011: internal medicine specialist at Malatya State Hospital; completed compulsory public service.
- 2015–2016: medical oncologist at Erzurum Ataturk Training and Research Hospital; completed compulsory public service.
- Since 2016: medical oncology specialist at Istinye University LIV Hospital.
- Since 2018: academic faculty member at Istinye University Vocational School of Health Services as an associate professor.
Tahsin Ozatli is the author and co-author of 13 scientific publications.
Tahsin Ozatli’s research focuses on identifying factors that improve cancer prognosis assessment and help determine the most appropriate treatment sequence. His publications include clinical case reports, single-center experience, and multicenter studies conducted by the Anatolian Society of Medical Oncology (ASMO).
- tumor molecular markers, including EGFR mutations in non-small cell lung cancer and KRAS discordance between primary and metastatic colorectal tumors;
- the efficacy and tolerability of drug therapy and chemoradiotherapy regimens for gastric cancer;
- prognostic factors and treatment sequencing in renal cell carcinoma, primary peritoneal carcinoma, and ovarian and uterine carcinosarcomas;
- rare tumors and complex clinical cases, including thoracic soft-tissue sarcoma, giant cell tumor of bone, rare breast cancer histology, and neuroendocrine tumors;
- metastatic involvement of the bone marrow and leptomeninges in cancer;
- multimodal treatment of complex lung tumors and EGFR mutation analysis presented in scientific conferences.
This research experience helps the doctor combine molecular diagnostic findings, the biological features of each tumor, and evidence on different treatment regimens when developing a personalized care plan.
Book: Body-mass Index and Health (2019), IntechOpen.
- Turkish Society of Medical Oncology (TTOD, 2012).
- Association of Oncology and Immunotherapy (OID, 2017).
Liv Istinye University Hospital in Istanbul is a multidisciplinary medical center where oncology patients can undergo diagnosis and treatment within one coordinated clinical team. Available services include laboratory testing, CT, MRI, PET-CT, endoscopic examinations, and pathology studies.
Treatment strategy is discussed by medical oncologists, surgeons, radiologists, radiation oncologists, and other relevant specialists. This approach helps the team review all findings and choose the appropriate sequence of care: drug therapy, surgery, radiotherapy, or a combination of these methods.
For international patients, the hospital can arrange an advance review of medical records, schedule consultations and examinations, provide support during treatment, and offer language assistance. This helps patients understand the expected care pathway, length of stay, and main treatment stages before traveling.
